Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (141-150 of 158) with videos related to

Pageof 16
Sort By:
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
Cancer|January 21, 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter studyAlessandra Iurlo, Daniele Cattaneo, Carmen Fava, et al.
Annals of Hematology|January 3, 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinibGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
American Journal of Hematology|April 11, 2018
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxisGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Blood Cancer Journal|June 10, 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML studyGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Leukemia|March 29, 2024
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Elza Lomaia, Christian Fabisch, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Leukemia|February 19, 2026
Development of a prognostic scoring system for chronic myeloid leukemia in blast phaseMichael Lauseker, Tomasz Sacha, Hana Klamova, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 16

Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
Cancer|January 21, 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter studyAlessandra Iurlo, Daniele Cattaneo, Carmen Fava, et al.
Annals of Hematology|January 3, 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinibGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
American Journal of Hematology|April 11, 2018
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxisGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Blood Cancer Journal|June 10, 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML studyGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Leukemia|March 29, 2024
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Elza Lomaia, Christian Fabisch, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Leukemia|February 19, 2026
Development of a prognostic scoring system for chronic myeloid leukemia in blast phaseMichael Lauseker, Tomasz Sacha, Hana Klamova, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 16